openPR Logo
Press release

Potential Analysis of Ebola drug and Vaccines Market Size by Key Manufacturers and Application with Share, Revenue and Forecast to 2022

04-01-2019 04:14 PM CET | Health & Medicine

Press release from: Allied Market Research

Potential Analysis of Ebola drug and Vaccines Market Size by Key

The new report by Allied Market Research titled, "Potential Analysis of Ebola drug and Vaccines Market - Global Opportunity Analysis and Industry Forecast to 2020" anticipates that the Ebola Virus Disease (EVD) vaccines would gain a market value of $56 million by 2020. The rampant growth of the disease in the underdeveloped economies and increasing awareness among people about life-threatening EVD disease has motivated healthcare authorities to introduce novel therapeutics.

Download the Sample Report @ https://www.alliedmarketresearch.com/request-sample/503?utm_source=openpr&utm_medium=Niranjan

Ebola, an orphan disease, has affected more than 20,000 people in African countries as of now. Recurring outbreaks of Ebola in the underdeveloped region and lack of effective therapies are factors that drive the need for Ebola drugs and vaccines.

The perennial outbreak of Ebola has given rise to a renewed interest among healthcare authorities in finding effective therapies. To control the EVD, the government authorities are supplying funds to pharmaceutical companies for research and development of EVD drugs and vaccines.

As an example, the government of the United States, through the FDA, has granted Fast Track designation to the Tekmiras TKM Ebola drug and has funded $140 million through the Department of defense, United States, for R&D on EVD. According to AMR analyst, Roshan Deshmukh, The prime focus of the companies is to commercialize the drugs and vaccines for EVD disease. The government authorities across the developed regions are extending support for the commercialization of these drugs by providing funds and floating favorable policies.

Flat 20% Discount on Purchase @ https://www.alliedmarketresearch.com/checkout/476172?utm_source=openpr&utm_medium=Niranjan

Normal symptoms such as simple viral fever are initially observed in patients infected with EVDs; however, at later stages, the consequences of these symptoms become deadly and leave no space for recovery. In the United States, EVD is termed as Quarantine able Communicable Diseases under section 361 (b) of the Public Health Service Act. This report tracks such key regulatory road maps and anticipated regulations in future by respective administrations. The report also focuses on the grass root ethical implications faced by players during clinical trials and other commercial activities.

3 MARKET OVERVIEW

3.1 Market Definition and Scope
3.2 Key Findings

3.2.1 Top factor impacting the market growth
3.2.2 Top investment pockets

3.3 Key market player positioning
3.4 Ebola Virus Key Facts

3.4.1 Transmission of Ebola
3.4.2 Signs and symptoms of Ebola
3.4.3 Diagnosis of Ebola
3.4.4 Vaccine or treatment available for Ebola

3.5 Amend for anti-Ebola disease drugs in the United States
3.6 Guidance on Air Medical Transport for Patients with Ebola Virus Disease
3.7 “Fast Track” designation to Anti-E bola drugs research from the U.S. government
3.8 ZMMP Drug: An Orphan solution for E-bola viral disease

3.8.1 ZMAPP is not ready for prime time

3.8.1.1 Orphan Drugs for Orphan Diseases

3.9 Ethical Dilemmas from therapeutics
3.10 Tekmira Pharma received the boost to ebola R&D through FDA fundings
3.11 Clinical Trials
3.12 Market Dynamics

3.12.1 Drivers

3.12.1.1 Prevalent cases and unpredictable nature of the disease
3.12.1.2 Increased rate of migration from developing countries
3.12.1.3 Lack of relevant medication

3.12.2 Restraints

3.12.2.1 High initial investment for R&D
3.12.2.2 Obstructive ethical considerations

3.12.3 Opportunities

3.12.3.1 Development of economic vaccines and drugs
3.12.3.2 Gaining a competitive edge in developing economies

About Us:-

Allied Market Research (AMR) is a full-service market research and business consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact Us:-

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Potential Analysis of Ebola drug and Vaccines Market Size by Key Manufacturers and Application with Share, Revenue and Forecast to 2022 here

News-ID: 1681776 • Views: 261

More Releases from Allied Market Research

North America Geogrid Market 2020 Segmentation, Demand, Growth, Trend, Opportuni …
According to the report published by Allied Market Research, the North America geogrid market generated $282.0 million in 2019, and is estimated to reach $408.25 million by 2027, registering a CAGR of 7.0% from 2020 to 2027. The report offers an extensive analysis of changing market dynamics, key winning strategies, business performance, major segments, and competitive scenarios. Surge in infrastructure development activities across the U.S. and Mexico and superior physical properties
Intravenous Immunoglobulin (IVIG) Market 2020 In-Depth Analysis of Industry Shar …
Global intravenous immunoglobulin market accounted for $8,995 million in 2017, and is projected to reach $15,964 million by 2025, registering a CAGR of 7.5% from 2018 to 2025. Immunoglobulin (Ig) is a plasma-derived product, which is obtained from the serum of healthy donors. The isolated plasma product is clinically treated and purified to Ig, which can be further used in the treatment of patients with antibody deficiency. Intravenous immunoglobulin (IVIG) finds
Asthma and COPD Drugs Market Is Expected to Witness a Steady Growth by 2026
"Asthma and COPD Drugs Market by Disease and Medication Class - Global Opportunity Analysis and Industry Forecasts, 2014-2022", projects that the global market for Asthma and COPD Drugs was valued at $38,960 million in 2015 and would reach $50,359 million by 2022, registering a CAGR of 3.7% from 2016 to 2022. Asthma segment dominated the market in 2015 and expected to continue its dominance throughout the forecast period. North America
Synthetic Biology Market in Global Industry by Top Companies, Type and Applicati …
Global Synthetic biology market is forecast to reach $38.7 billion by 2020, at a CAGR of 44.2% during the forecast period (2014 - 2020). Europe occupies largest share in the global market and would hold-on to its position throughout 2020. However, Asia Pacific is the fastest growing market with a CAGR of 46.4% from 2014 - 2020. Read Full Report @ https://www.alliedmarketresearch.com/synthetic-biology-market Synthetic biology is at a nascent stage and has recently

All 5 Releases


More Releases for Ebola

Ebola Vaccine Market Opportunity Analysis, 2018-2026
Ebola virus disease (EVD) causes viral hemorrhagic fever. It is a life threatening disease, which is spread to humans from animals. Direct contact with body fluids of infected person is one of largest causes of spread of this infection. Symptoms of Ebola disease include high fever, vomiting, sore throat, diarrhea, headache and muscular pain, and in few cases, internal or external bleeding. Although, there is no cure for Ebola virus
Ebola Treatment Market: Global Industry Analysis and Forecast 2016 - 2024
Ebola viral infection was first observed in The Democratic Republic of Congo (named after a river called Zaire) in 1976. Ebola is a viral disease which frequently causes lethal haemorrhagic fever in humans. The harmful consequences of Ebola viral infection are that the viruses can be used as potential biological weapon. The symptoms of Ebola viral infection include sudden onset of fever, sore throat, headaches, extreme tiredness, vomiting, skin rash,
2017-2022 Global Ebola Virus Vaccine Industry Forecast Report
ReportsWeb.com has announced the addition of the “Global Ebola Virus Vaccine Market Research Report 2017-2022” The report focuses on global major leading players with information such as company profiles, product picture and specification. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD) , market share and growth rate of Ebola Virus Vaccine in these regions, from 2012 to 2022 (forecast) , covering North America, Europe,
Ebola Virus Vaccine Market & Pipeline Insight
Ebola virus infection, which was previously called Ebola hemorrhagic fever was discovered in 1976. The infection caused due to ebola virus originates from four different strains of ebola virus. These viruses generally are known to affect non-human primates, and are transmitted from wild animals to the humans and among the latter, it is known to spread through human-to-human transmission. The natural hosts of ebola virus are Fruit bats, which
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Review, H1 2017 to its growing collection of premium market research reports. Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline Review, H1 2017, provides an overview of the Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) pipeline landscape. Ebola is a rare but deadly viral infection that
Ebola Drug and Vaccine Market - Global Industry Analysis 2016 - 2024
Ebola has emerged as a major hazard to mankind in recent years. Though the Ebola virus and the disease caused by it have been familiar to science for decades, the risk of a global epidemic has increased massively due to the advances in globalization. The recent outbreak of Ebola in West Africa has brought the disease in the global spotlight. Ebola starts out as a sore throat, muscle pain, headache, and